SOM BIOTECH

You are here: Home

Drug-Discovery Platform (PCB) and SOM Biotech agreement

Mar 8^th, 2012

The Drug-Discovery Platform from the Barcelona Science Park licenses SOM Biotech up to 219 reprofiling drugs to be developed by the company.

Latest News

QUICK LINKS

Hot News

Repurposing drugs; more than $20Billion in sales

September, 2012

A recent Thomson Reuters report indicates that drug repositioning is expected to generate up to $20Billion in annual sales during 2012, thus opening up a new source of revenue to large, medium and small Pharma companies.

SOM Biotech in New European Economy

Winter, 2012

SOM Biotech, has been identified as one of the best opportunities to invest in start-up biopharmaceuticals companies in Catalonia. Link: http://www.neweuropeaneconomy.com/home-mainmenu-51/fdi-mainmenu-59/514-adding-value-to-existing-drugs

SOM0226 presented at the XIIIth International Symposium on Amyloidosis

May 6^th-10^th, 2012

SOM0226, a reprofiled drug for the treatment of TTR amyloidosis, has been presented at the XIII^th International Symposium on Amyloidosis in Groningen, The Netherlands. The product has been recognized as one of the most promising in-coming therapies by the scientific expert community in the field.